Skip to main content

Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

The Original Article was published on 13 May 2020

Correction to: Mol Cancer 19, 90 (2020)

https://doi.org/10.1186/s12943-020-01202-9

Following the publication of the original paper [1], the authors found minor typographical errors that should be corrected.

In the Results section, the dosage of ASK120067 in the sentence “we present a preliminary result of a patient in this clinical study with a confirmed radiographic response after treatment with the lowest dose (40 mg/kg once daily)” has been corrected to “…with the lowest dose (40 mg once daily)”.

In the figure legend of Figure 3g, the sentence “Computed tomography scans of the chest from a patient before and after treatment with 40 mg/kg ASK120067 in a phase I trial…” has been corrected to “…treatment with 40 mg ASK120067 once daily in a phase I trial…”.

These corrections have no impact on the results or conclusions of the study.

The original article has been corrected.

Reference

  1. Zhang T, Qu R, Chan S, et al. Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. Mol Cancer. 2020;19:90. https://doi.org/10.1186/s12943-020-01202-9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Ke Ding, Jian Ding or Hua Xie.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zhang, T., Qu, R., Chan, S. et al. Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. Mol Cancer 20, 102 (2021). https://doi.org/10.1186/s12943-021-01391-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s12943-021-01391-x